Vistagen Therapeutics Inc. (VSTA) 10.0000 $VSTA
VistaGen Receives Notice of Allowance for Canadian Patent Further Expanding Stem Cell Technology Platform
Marketwire - Tue Aug 19, 8:30AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue, drug discovery and regenerative medicine, today announces that the Canadian Intellectual Property Office has issued a Notice of Allowance for Canadian Patent Application No. 2,487,058, entitled "Mesoderm and Definitive Endoderm Cell Populations." This patent, which is licensed exclusively to VistaGen by the Icahn School of Medicine at Mount Sinai in New York, will further expand VistaGen's intellectual property portfolio for pluripotent stem cell culture systems that produce human cells of the endoderm lineage, including liver, lung, pancreas, parathyroid and thyroid cells.
VistaGen approves one for-20 reverse split reverse stock split
M2 - Thu Aug 14, 3:05AM CDT
Stem cell company VistaGen Therapeutics (OTCQB:VSTA) reported on Wednesday the authorisation of a one for-20 reverse split of its common stock.
VistaGen Announces Reverse Stock Split
Marketwire - Wed Aug 13, 5:21PM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a stem cell company focused on drug rescue, drug discovery and regenerative medicine, announced today that will implement a 1-for-20 reverse split of its common stock effective at the opening of trading on August 14, 2014. At that time, VistaGen's common stock will trade on a split-adjusted basis under new CUSIP number 92840H202 and temporary symbol "VSTAD," with the "D" appended to signify that the reverse stock split has occurred. VistaGen's trading symbol will revert to "VSTA" after approximately 20 trading days.
VistaGen Therapeutics, Inc. - Product Pipeline Review - 2014
M2 - Fri Jul 25, 3:32AM CDT
Summary
VistaGen Therapeutics, Inc. (VSTA) - Product Pipeline Analysis
M2 - Fri Jul 11, 3:24AM CDT
Summary
VistaGen Receives Notice of Allowance for Canadian Patent Expanding Stem Cell Technology Platform
Marketwire - Mon Jun 16, 8:30AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue and regenerative medicine, today announces that the Canadian Intellectual Property Office has issued a Notice of Allowance for Canadian patent No. 2,684,022, entitled "Mesoderm and Definitive Endoderm Cell Populations." This patent, which is licensed exclusively to VistaGen by the Icahn School of Medicine at Mount Sinai in New York, will expand VistaGen's intellectual property portfolio for pluripotent stem cell culture systems that produce human cells of the endoderm lineage, including liver, lung, pancreas, parathyroid and thyroid cells.
OTC Signal Daily Stock Watch - VistaGen (OTCQB: VSTA)
WorldStockWire - Mon Sep 09, 1:00AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Lymphoma - Pipeline Review, H2 2013 Reveals the Latest News and Deals Relating to the Products
M2 - Wed Sep 04, 9:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/37s3zw/lymphoma) has announced the addition of the "Lymphoma - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lymphoma. Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Lymphoma. - A review of the Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lymphoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. Some of the Companies Mentioned: - Bristol-Myers Squibb Company - Genzyme Corporation - Biogen Idec Inc. - Allergan, Inc. - Shionogi & Co., Ltd. - Sanofi-Aventis - AstraZeneca PLC - Quark Pharmaceuticals, Inc. - Daiichi Sankyo Company, Ltd - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Sangamo BioSciences, Inc. - XenoPort, Inc. - BioLineRx, Ltd. - LEO Pharma A/S - Pfizer Inc. - Sun Pharmaceutical Industries Limited - VistaGen Therapeutics , Inc. - Palau Pharma S.A - Snowdon Inc. - Neurotune AG - AngioChem Inc. - PharmEste - Trevena, Inc. - MediProPharma, Inc. - Celtic Pharmaceutical Holdings L.P. - Vichem Chemie Research Ltd. - RaQualia Pharma Inc. - Naurex, Inc. - Cytogel Pharma, LLC For more information visit http://www.researchandmarkets.com/research/37s3zw/lymphoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
VistaGen Provides Update on $36 Million Strategic Financing Agreement
Marketwire - Fri Jun 28, 11:13AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announced an update on the status of its strategic financing agreement with Autilion AG.
VistaGen Therapeutics Presents CardioSafe 3D(TM) and LiverSafe 3D(TM) Developments at International Society of Stem Cell Research's 11th Annual Meeting
Marketwire - Mon Jun 17, 9:29AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, presented key developments involving its CardioSafe 3D(TM) and LiverSafe 3D(TM) bioassay systems in poster presentations at the 11th Annual Meeting of the International Society of Stem Cell Research (ISSCR), the largest forum for stem cell and regenerative medicine professionals from around the world, held June 12 to 15, 2013, in Boston, Massachusetts.
VistaGen Therapeutics and Duke University Publish Results on Production of Functional 3D Human Heart Tissue
Marketwire - Tue May 07, 7:00AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, announced that its high-quality, human pluripotent stem cell-derived cardiomyocytes (heart cells) were used by collaboration partner Duke University to grow a revolutionary three-dimensional (3D) human heart muscle. An abstract of the original research article published in Biomaterials, an international journal covering the science and clinical application of biomaterials, can be found online at: http://www.sciencedirect.com/science/article/...1213004705.
VistaGen Therapeutics Inc signs USD36m strategic financing agreement with Bergamo Acquisition Corp's European subsidiary
M2 - Thu Apr 11, 9:41AM CDT
Biotechnology company VistaGen Therapeutics Inc (OTCQB:VSTA) said on Wednesday that it has entered into a USD36m strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp (OTC: BGMO), an investment holding company.
UPDATE: VistaGen Announces $36 Million Strategic Financing Agreement
Marketwire - Wed Apr 10, 12:25PM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces the signing of a strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp. (OTC: BGMO), a global diversified investment holding company.
VistaGen Announces $36 Million Strategic Financing Agreement
Marketwire - Wed Apr 10, 7:50AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces the signing of a strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp. (PINKSHEETS: BGMO), a global diversified investment holding company.
VistaGen Therapeutics to Present Enhancements and Expanded Validation of LiverSafe 3D(TM) at Society of Toxicology's 52nd Annual Meeting
Marketwire - Tue Mar 12, 10:08AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces that it will present key enhancements to LiverSafe 3D(TM), its human liver cell-based bioassay system designed to predict liver toxicity and drug metabolism issues, in a poster presentation at the Society of Toxicology's 52nd Annual Meeting, the world's premier toxicology conference, in San Antonio, Texas, on March 12, 2013, at 11:00 am PDT.
VistaGen Therapeutics to Present CardioSafe 3D(TM) Developments at Society of Toxicology's 52nd Annual Meeting
Marketwire - Mon Mar 11, 9:00AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces it will feature key developments involving CardioSafe 3D(TM), its pluripotent stem cell-based bioassay system for heart toxicity, in a poster presentation at the Society of Toxicology's 52nd Annual Meeting, the world's premier toxicology conference, in San Antonio, Texas, on March 11, 2013, at 7:30 am PDT.
VistaGen Therapeutics Enters Strategic Collaboration With Celsis to Further Advance LiverSafe 3D(TM)
Marketwire - Mon Mar 04, 8:02AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, and Celsis In Vitro Technologies ("Celsis"
, the premier global provider of specialized in vitro products for drug metabolism, drug-drug interaction and toxicity screening, have entered into a new strategic collaboration agreement. The comprehensive goal of the agreement is to characterize and functionally benchmark VistaGen's human liver cell platform, LiverSafe 3D(TM), for studying and predicting human liver drug metabolism.
VistaGen's Collaborators Identify Definitive Precursor for Adult Blood and the Immune System
Marketwire - Thu Feb 07, 9:07AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announced significant advancements in its stem cell technology licensed from the University Health Network (UHN) in Toronto, Canada. The advancements, which improve VistaGen's ability to develop new stem cell-based bioassay systems and potentially improved cell therapies for human blood system disorders, were reported in the December 2012 edition of Cell Reports, an open-access journal from Cell Press.
Vistagen Therapeutics Successfully Completes Final Phase 1 Safety Study of AV-101
Marketwire - Wed Jan 23, 7:30AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced the successful completion of its final Phase 1 safety study of AV-101, a novel orally available prodrug candidate being developed for treatment of multiple conditions involving chronic neuropathic pain. The study results indicate that AV-101 is safe and well tolerated, with favorable bioavailability and pharmacokinetics.
VistaGen Therapeutics to Present at Noble Financial Capital Markets Ninth Annual Equity Conference
Marketwire - Tue Jan 22, 5:00AM CST
VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced that Shawn K. Singh, CEO of VistaGen, will present at Noble Financial Capital Markets' Ninth Annual Equity Conference.
VistaGen Receives Notice of Allowance for Canadian Patent Further Expanding Stem Cell Technology Platform
Marketwire - Tue Aug 19, 8:30AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue, drug discovery and regenerative medicine, today announces that the Canadian Intellectual Property Office has issued a Notice of Allowance for Canadian Patent Application No. 2,487,058, entitled "Mesoderm and Definitive Endoderm Cell Populations." This patent, which is licensed exclusively to VistaGen by the Icahn School of Medicine at Mount Sinai in New York, will further expand VistaGen's intellectual property portfolio for pluripotent stem cell culture systems that produce human cells of the endoderm lineage, including liver, lung, pancreas, parathyroid and thyroid cells.
VistaGen approves one for-20 reverse split reverse stock split
M2 - Thu Aug 14, 3:05AM CDT
Stem cell company VistaGen Therapeutics (OTCQB:VSTA) reported on Wednesday the authorisation of a one for-20 reverse split of its common stock.
VistaGen Announces Reverse Stock Split
Marketwire - Wed Aug 13, 5:21PM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a stem cell company focused on drug rescue, drug discovery and regenerative medicine, announced today that will implement a 1-for-20 reverse split of its common stock effective at the opening of trading on August 14, 2014. At that time, VistaGen's common stock will trade on a split-adjusted basis under new CUSIP number 92840H202 and temporary symbol "VSTAD," with the "D" appended to signify that the reverse stock split has occurred. VistaGen's trading symbol will revert to "VSTA" after approximately 20 trading days.
VistaGen Therapeutics, Inc. - Product Pipeline Review - 2014
M2 - Fri Jul 25, 3:32AM CDT
Summary
VistaGen Therapeutics, Inc. (VSTA) - Product Pipeline Analysis
M2 - Fri Jul 11, 3:24AM CDT
Summary
VistaGen Receives Notice of Allowance for Canadian Patent Expanding Stem Cell Technology Platform
Marketwire - Mon Jun 16, 8:30AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue and regenerative medicine, today announces that the Canadian Intellectual Property Office has issued a Notice of Allowance for Canadian patent No. 2,684,022, entitled "Mesoderm and Definitive Endoderm Cell Populations." This patent, which is licensed exclusively to VistaGen by the Icahn School of Medicine at Mount Sinai in New York, will expand VistaGen's intellectual property portfolio for pluripotent stem cell culture systems that produce human cells of the endoderm lineage, including liver, lung, pancreas, parathyroid and thyroid cells.
OTC Signal Daily Stock Watch - VistaGen (OTCQB: VSTA)
WorldStockWire - Mon Sep 09, 1:00AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Lymphoma - Pipeline Review, H2 2013 Reveals the Latest News and Deals Relating to the Products
M2 - Wed Sep 04, 9:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/37s3zw/lymphoma) has announced the addition of the "Lymphoma - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lymphoma. Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Lymphoma. - A review of the Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lymphoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. Some of the Companies Mentioned: - Bristol-Myers Squibb Company - Genzyme Corporation - Biogen Idec Inc. - Allergan, Inc. - Shionogi & Co., Ltd. - Sanofi-Aventis - AstraZeneca PLC - Quark Pharmaceuticals, Inc. - Daiichi Sankyo Company, Ltd - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Sangamo BioSciences, Inc. - XenoPort, Inc. - BioLineRx, Ltd. - LEO Pharma A/S - Pfizer Inc. - Sun Pharmaceutical Industries Limited - VistaGen Therapeutics , Inc. - Palau Pharma S.A - Snowdon Inc. - Neurotune AG - AngioChem Inc. - PharmEste - Trevena, Inc. - MediProPharma, Inc. - Celtic Pharmaceutical Holdings L.P. - Vichem Chemie Research Ltd. - RaQualia Pharma Inc. - Naurex, Inc. - Cytogel Pharma, LLC For more information visit http://www.researchandmarkets.com/research/37s3zw/lymphoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
VistaGen Provides Update on $36 Million Strategic Financing Agreement
Marketwire - Fri Jun 28, 11:13AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announced an update on the status of its strategic financing agreement with Autilion AG.
VistaGen Therapeutics Presents CardioSafe 3D(TM) and LiverSafe 3D(TM) Developments at International Society of Stem Cell Research's 11th Annual Meeting
Marketwire - Mon Jun 17, 9:29AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, presented key developments involving its CardioSafe 3D(TM) and LiverSafe 3D(TM) bioassay systems in poster presentations at the 11th Annual Meeting of the International Society of Stem Cell Research (ISSCR), the largest forum for stem cell and regenerative medicine professionals from around the world, held June 12 to 15, 2013, in Boston, Massachusetts.
VistaGen Therapeutics and Duke University Publish Results on Production of Functional 3D Human Heart Tissue
Marketwire - Tue May 07, 7:00AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, announced that its high-quality, human pluripotent stem cell-derived cardiomyocytes (heart cells) were used by collaboration partner Duke University to grow a revolutionary three-dimensional (3D) human heart muscle. An abstract of the original research article published in Biomaterials, an international journal covering the science and clinical application of biomaterials, can be found online at: http://www.sciencedirect.com/science/article/...1213004705.
VistaGen Therapeutics Inc signs USD36m strategic financing agreement with Bergamo Acquisition Corp's European subsidiary
M2 - Thu Apr 11, 9:41AM CDT
Biotechnology company VistaGen Therapeutics Inc (OTCQB:VSTA) said on Wednesday that it has entered into a USD36m strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp (OTC: BGMO), an investment holding company.
UPDATE: VistaGen Announces $36 Million Strategic Financing Agreement
Marketwire - Wed Apr 10, 12:25PM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces the signing of a strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp. (OTC: BGMO), a global diversified investment holding company.
VistaGen Announces $36 Million Strategic Financing Agreement
Marketwire - Wed Apr 10, 7:50AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces the signing of a strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp. (PINKSHEETS: BGMO), a global diversified investment holding company.
VistaGen Therapeutics to Present Enhancements and Expanded Validation of LiverSafe 3D(TM) at Society of Toxicology's 52nd Annual Meeting
Marketwire - Tue Mar 12, 10:08AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces that it will present key enhancements to LiverSafe 3D(TM), its human liver cell-based bioassay system designed to predict liver toxicity and drug metabolism issues, in a poster presentation at the Society of Toxicology's 52nd Annual Meeting, the world's premier toxicology conference, in San Antonio, Texas, on March 12, 2013, at 11:00 am PDT.
VistaGen Therapeutics to Present CardioSafe 3D(TM) Developments at Society of Toxicology's 52nd Annual Meeting
Marketwire - Mon Mar 11, 9:00AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces it will feature key developments involving CardioSafe 3D(TM), its pluripotent stem cell-based bioassay system for heart toxicity, in a poster presentation at the Society of Toxicology's 52nd Annual Meeting, the world's premier toxicology conference, in San Antonio, Texas, on March 11, 2013, at 7:30 am PDT.
VistaGen Therapeutics Enters Strategic Collaboration With Celsis to Further Advance LiverSafe 3D(TM)
Marketwire - Mon Mar 04, 8:02AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, and Celsis In Vitro Technologies ("Celsis"
, the premier global provider of specialized in vitro products for drug metabolism, drug-drug interaction and toxicity screening, have entered into a new strategic collaboration agreement. The comprehensive goal of the agreement is to characterize and functionally benchmark VistaGen's human liver cell platform, LiverSafe 3D(TM), for studying and predicting human liver drug metabolism. VistaGen's Collaborators Identify Definitive Precursor for Adult Blood and the Immune System
Marketwire - Thu Feb 07, 9:07AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announced significant advancements in its stem cell technology licensed from the University Health Network (UHN) in Toronto, Canada. The advancements, which improve VistaGen's ability to develop new stem cell-based bioassay systems and potentially improved cell therapies for human blood system disorders, were reported in the December 2012 edition of Cell Reports, an open-access journal from Cell Press.
Vistagen Therapeutics Successfully Completes Final Phase 1 Safety Study of AV-101
Marketwire - Wed Jan 23, 7:30AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced the successful completion of its final Phase 1 safety study of AV-101, a novel orally available prodrug candidate being developed for treatment of multiple conditions involving chronic neuropathic pain. The study results indicate that AV-101 is safe and well tolerated, with favorable bioavailability and pharmacokinetics.
VistaGen Therapeutics to Present at Noble Financial Capital Markets Ninth Annual Equity Conference
Marketwire - Tue Jan 22, 5:00AM CST
VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced that Shawn K. Singh, CEO of VistaGen, will present at Noble Financial Capital Markets' Ninth Annual Equity Conference.
